News & Press Release 2018-08-15Press Release Lunabell® Compound Tablets LD and ULD Authorized Generic[65 KB] 2018-07-02Press Release Jemina® tablets（NPC-16）Approved in Japan for the Treatment of Dysmemorrhea 2018-07-02Press Release Announcing Sales Launch of TITANBRIDGE® First Medical Device to Receive SAKIGAKE Designation Medical Device for the Treatment of Adductor Spasmodic Dysphonia[99 KB] 2018-06-06Press Release Launch of RAPALIMUS® GEL 0.2% SAKIGAKE Designation & Orphan Drug Designation Treatment for Angiofibroma in Tuberous Sclerosis Complex[154 KB] 2018-05-31Press Release Announcement of Personnel Changes[43 KB] 2018-05-15Press Release Announcement of Private Placement of Shares to MEDIPAL HOLDINGS CORPORATION[118 KB] 2018-03-26Press Release Announcement of Personnel Changes[65 KB] 2018-03-26Press Release Marketing Approval Granted for RAPALIMUS GEL 0.2% (mTOR inhibitor), SAKIGAKE Designation & Orphan Drug Designation to Treat Angiofibroma in Tuberous Sclerosis Complex[51 KB] Nobelpharma About Nobelpharma Message from President & CEO Corporate Identity Philosophy Origin of Company Name History Company Company Profile Map & Directions Organization Chart Board Members Research & Development R&D of Nobelpharma Pipeline Products Financial Information Financial Highlights Financial Reports
